The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK/06/016).
 
Isabel Syndikus
Honoraria - AstraZeneca; Bristol-Myers Squibb/Pfizer; Janssen; Roche
Travel, Accommodations, Expenses - Bayer; Janssen
 
Clare Griffin
Research Funding - Accuray (Inst)
 
Lara Philipps
No Relationships to Disclose
 
Alison Tree
Leadership - Elekta MRL Consortium (Inst)
Honoraria - Accuray; Elekta; Janssen (Inst)
Research Funding - Accuray (Inst); Elekta (Inst)
Travel, Accommodations, Expenses - Elekta MRL Consortium
 
Vincent Khoo
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Bayer; Boston Scientific; Janssen Oncology
Speakers' Bureau - Accuray; Bayer UK; Boston Scientific; Janssen Oncology
Travel, Accommodations, Expenses - Accuray; Bayer; Boston Scientific; Janssen Oncology
 
Alison Jane Birtle
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Bristol-Myers-Squib; Janssen Oncology; Merck Serono; Pfizer; Roche; Sanofi
Speakers' Bureau - Bayer; Janssen Oncology; Pfizer
Research Funding - Genzyme
 
Ananya Choudhury
Honoraria - American Society of Therapeutic Radiation Oncology; ASCO/Pfizer Grant; Bayer; Elekta; Genentech/Roche; Janssen Oncology
Research Funding - Elekta (Inst)
Travel, Accommodations, Expenses - Bayer; Elekta
 
Catherine Ferguson
No Relationships to Disclose
 
Joe M. O'Sullivan
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Novartis; Sanofi
Speakers' Bureau - Bayer; Janssen; Novartis
Research Funding - Bayer (Inst)
 
Miguel Panades
No Relationships to Disclose
 
Yvonne L. Rimmer
No Relationships to Disclose
 
Christopher D. Scrase
No Relationships to Disclose
 
John Staffurth
Leadership - Lodge Oncology Consulting Ltd
Stock and Other Ownership Interests - Lodge Oncology Consulting Ltd
Consulting or Advisory Role - Accord Healthcare; Novartis
 
Clare Cruickshank
No Relationships to Disclose
 
Shama Hassan
No Relationships to Disclose
 
Julia Pugh
No Relationships to Disclose
 
David P. Dearnaley
Consulting or Advisory Role - Janssen Oncology
Patents, Royalties, Other Intellectual Property - Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. Professor Dearnaley is on the Institute’s Rewards to Inventors list for abiraterone acetate. (Inst); Patent issued EP1933709B1 (location and stabilisation device)
 
Emma Hall
Research Funding - Accuray (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst); Merck Sharpe & Dohme (Inst); Roche (Inst); Varian Medical Systems (Inst)